| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2016 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EQRx, Inc. | 4 | Q3 2022 | 61.9% |
| Nautilus Biotechnology, Inc. | 4 | Q3 2022 | 40.8% |
| Erasca, Inc. | 4 | Q3 2022 | 20.3% |
| InVitae Corporation | 4 | Q3 2022 | 9.3% |
View AH Equity Partners Bio II, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-11-09 |
| 4 | 2023-01-04 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 3 | 2021-12-22 |
| 3 | 2021-06-09 |
View AH Equity Partners Bio II, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.